How to Safely Stop Antidepressants: Overcoming Depression in France

In France, depression remains a widespread mental health concern, prompting many to rely on antidepressant medications. Understanding effective strategies for safely discontinuing these drugs is increasingly important as individuals seek alternative paths to recovery.

The Overlooked Challenge of Antidepressant Discontinuation

For years, the issue of deprescribing antidepressants barely surfaced in medical training or clinical practice. Today, however, the topic has gained prominence among both psychiatrists and their patients. According to Maeva Musso, president of the French Association of Young Psychiatrists and Addictologists, “Throughout my residency, which ended quite recently, this question was never addressed in teaching.” Now, more patients are requesting to reduce or end their treatment—although some doctors still view this as a form of denial regarding the underlying illness.

New Research Sheds Light on Best Practices

A recent international study led by Giovanni Ostuzzi and Debora Zaccoletti, published in The Lancet Psychiatry, systematically analyzed 76 clinical trials involving over 17,000 participants. The findings? Patients who tapered off antidepressants gradually—while receiving robust psychological support—faced no higher risk of relapse compared to those who continued treatment. Conversely, abruptly stopping medication is strongly discouraged due to significant relapse risks.

The Essential Role of Psychological Support

These results come with an important caveat: psychological assistance makes a marked difference. Even with a slow taper, the absence of mental health support can heighten the risk of recurrence. As German psychiatrist Jonathan Henssler commented in the same journal, “Even very gradual reduction is still associated with some risk of relapse. The additional benefit of psychotherapy is obvious.” Unfortunately, not everyone has access to such services.

In France especially, barriers to proper care persist. According to Christine Villelongue, co-president of France Depression, there is an ongoing “shortage” of trained professionals, complicating an already sensitive transition for many individuals.

Differing International Approaches—and Persistent Inequalities

Some countries are tackling these challenges head-on. For instance:

• Norway offers specialized consultations for discontinuation;
• The Netherlands allows reductions using microdoses for exceptional graduality.

In contrast, France still struggles to provide individualized withdrawal plans. As Debora Zaccoletti notes, while antidepressants prevent depressive relapses effectively, long-term use should not be automatic or universal.

Recent developments signal growing awareness—but also highlight persistent disparities in depression management and access to essential services across regions. The path forward demands not just clinical evidence but also equitable support structures for every patient considering change.